Literature DB >> 17605055

Sensitivity and specificity of a commercial C6 peptide enzyme immuno assay in diagnosis of acute Lyme neuroborreliosis.

T Skarpaas1, U Ljøstad, M Søbye, A Mygland.   

Abstract

The purpose of this study was to evaluate the diagnostic sensitivity and specificity of a commercial C6 enzyme immuno assay, QuickC6, in acute Lyme neuroborreliosis (LNB) in endemic areas. Paired sera and cerebral spinal fluids (CSFs) from 60 patients with definite LNB, eight patients with possible LNB, 18 patients with conditions mimicking LNB and 42 persons with noninfectious neurological disease were examined. The case definition of LNB was based on strict criteria during a prospective 4-month follow-up. The sensitivity of QuickC6 was 98% both in sera and CSFs, and the diagnostic specificity was 61% in sera and 88% in CSFs. QuickC6 is a sensitive, simple and cost-effective screening test in serum and CSF in diagnosis of acute LNB. Specificity needs further evaluation.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17605055     DOI： 10.1007/s10096-007-0336-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  10 in total

1.  [Neuroborreliosis in Vest-Agder].

Authors:  Unn Ljøstad; Ase Mygland; Tone Skarpaas
Journal:  Tidsskr Nor Laegeforen       Date:  2003-03-06

2.  Evaluation of the C6 peptide enzyme-linked immunosorbent assay for individuals vaccinated with the recombinant OspA vaccine.

Authors:  Adriana R Marques; Dale S Martin; Mario T Philipp
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

Review 3.  European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis.

Authors:  G Stanek; S O'Connell; M Cimmino; E Aberer; W Kristoferitsch; M Granström; E Guy; J Gray
Journal:  Wien Klin Wochenschr       Date:  1996-12-13       Impact factor: 1.704

4.  Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE.

Authors:  F T Liang; A C Steere; A R Marques; B J Johnson; J N Miller; M T Philipp
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 5.  Diagnosis of lyme borreliosis.

Authors:  Maria E Aguero-Rosenfeld; Guiqing Wang; Ira Schwartz; Gary P Wormser
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

6.  Comparative reactivity of human sera to recombinant VlsE and other Borrelia burgdorferi antigens in class-specific enzyme-linked immunosorbent assays for Lyme borreliosis.

Authors:  Louis A Magnarelli; Matthew Lawrenz; Steven J Norris; Erol Fikrig
Journal:  J Med Microbiol       Date:  2002-08       Impact factor: 2.472

Review 7.  Diagnosis of lyme borreliosis in europe.

Authors:  Bettina Wilske
Journal:  Vector Borne Zoonotic Dis       Date:  2003       Impact factor: 2.133

8.  Lyme neuroborreliosis: a new sensitive diagnostic assay for intrathecal synthesis of Borrelia burgdorferi--specific immunoglobulin G, A, and M.

Authors:  K Hansen; A M Lebech
Journal:  Ann Neurol       Date:  1991-08       Impact factor: 10.422

9.  Diagnosis of Lyme neuroborreliosis with antibodies to recombinant proteins DbpA, BBK32, and OspC, and VlsE IR6 peptide.

Authors:  Jaana Panelius; Pekka Lahdenne; Harri Saxén; Sten-Anders Carlsson; Tero Heikkilä; Miikka Peltomaa; Anneli Lauhio; Ilkka Seppälä
Journal:  J Neurol       Date:  2003-11       Impact factor: 4.849

10.  Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates.

Authors:  Rendi Murphree Bacon; Brad J Biggerstaff; Martin E Schriefer; Robert D Gilmore; Mario T Philipp; Allen C Steere; Gary P Wormser; Adriana R Marques; Barbara J B Johnson
Journal:  J Infect Dis       Date:  2003-04-02       Impact factor: 5.226
  10 in total
  6 in total

1.  Study of a Cohort of 1,886 Persons To Determine Changes in Antibody Reactivity to Borrelia burgdorferi 3 Months after a Tick Bite.

Authors:  Ram B Dessau; Linda Fryland; Peter Wilhelmsson; Christina Ekerfelt; Dag Nyman; Pia Forsberg; Per-Eric Lindgren
Journal:  Clin Vaccine Immunol       Date:  2015-05-20

2.  Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease.

Authors:  Gary P Wormser; Martin Schriefer; Maria E Aguero-Rosenfeld; Andrew Levin; Allen C Steere; Robert B Nadelman; John Nowakowski; Adriana Marques; Barbara J B Johnson; J Stephen Dumler
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-11       Impact factor: 2.803

3.  Retrospective Evaluation of Various Serological Assays and Multiple Parameters for Optimal Diagnosis of Lyme Neuroborreliosis in a Routine Clinical Setting.

Authors:  Tamara van Gorkom; Willem Voet; Gijs H J van Arkel; Michiel Heron; B J A Hoeve-Bakker; Daan W Notermans; Steven F T Thijsen; Kristin Kremer
Journal:  Microbiol Spectr       Date:  2022-06-21

Review 4.  The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis.

Authors:  M M G Leeflang; C W Ang; J Berkhout; H A Bijlmer; W Van Bortel; A H Brandenburg; N D Van Burgel; A P Van Dam; R B Dessau; V Fingerle; J W R Hovius; B Jaulhac; B Meijer; W Van Pelt; J F P Schellekens; R Spijker; F F Stelma; G Stanek; F Verduyn-Lunel; H Zeller; H Sprong
Journal:  BMC Infect Dis       Date:  2016-03-25       Impact factor: 3.090

5.  Commercial test kits for detection of Lyme borreliosis: a meta-analysis of test accuracy.

Authors:  Michael J Cook; Basant K Puri
Journal:  Int J Gen Med       Date:  2016-11-18

6.  Lyme arthritis in Southern Norway--an endemic area for Lyme borreliosis.

Authors:  Glenn Haugeberg; Inger Johanne W Hansen; Tone Skarpaas; Sølvi Noraas; Vivian Kjelland
Journal:  BMC Infect Dis       Date:  2014-04-05       Impact factor: 3.090
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.